Skip to content

PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction

PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02282072
Enrollment
20
Registered
2014-11-04
Start date
2016-12-31
Completion date
2018-12-31
Last updated
2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Addiction

Brief summary

The purpose of this study is to verify efficacy and safety of a bilateral deep brain stimulation (DBS) of the Nucleus accumbens (NAc) as a treatment option for severe opioid addiction.

Interventions

DEVICEDeep brain stimulation:PINS Stimulation System

Sponsors

Beijing Tiantan Hospital
CollaboratorOTHER
Beijing Pins Medical Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \> 18 years old. 2. In accordance with the diagnostic standards of DSM-IV & ICD-10 for addicted and DSM-IV for abstinence. 3. Qualitative urine detection for opioids showing positive result. 4. Cleared for 8 to 36 hours after their last drug taking. 5. Fully understood and signed on informed consent.

Exclusion criteria

1. Person with consciousness disorder on opioid abstinence, seriously aggressive, heavily dehydrated and intending to commit suicide. 2. Patients with serious liver and kidney dysfunction, pulmonary decompensation, or complicated with serious damage in other systems. 3. Patients with serious infectious disease. 4. Patients with history of serious neurological or psychiatrical diseases. 5. Person with history of HIV infection or serious malnutrition. 6. Dependent upon and addicted to multiple drugs. 7. Attended some other drug trials within one month.

Design outcomes

Primary

MeasureTime frame
Schedule for the Assessment of Negative Symptoms (SANS)6 month

Secondary

MeasureTime frame
Chronic Hunger Scale6 month
Beck Depression Inventory6 month
Buss & Perry Aggression Questionnaire6 month

Countries

China

Contacts

Primary ContactJia Fumin, PhD
pins_medical@163.com+86 010-59361265

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026